(-)-OSU6162治疗动脉瘤性蛛网膜下腔出血后疲劳及其他后遗症的双盲随机安慰剂对照研究
本研究为双盲随机安慰剂对照单中心试验,纳入96例动脉瘤性蛛网膜下腔出血后疲劳患者,给予(-)-OSU6162 30-60 mg/日或安慰剂治疗12周。结果显示两组疲劳严重程度量表(FSS)、精神疲劳量表(MFS)和贝克抑郁量表II(BDI-II)评分均显著改善,但组间无显著差异;(-)-OSU6162仅在完全重返工作的患者中显著改善FSS评分。
要点
- (-)-OSU6162与安慰剂在改善aSAH后疲劳及其他后遗症方面疗效相似。
- 完全重返工作的患者中,(-)-OSU6162显著改善FSS评分。
- (-)-OSU6162组头晕报告更常见,但无严重不良事件归因于治疗。
核心结论
- (-)-OSU6162与安慰剂对aSAH后疲劳及其他后遗症的缓解作用相似。
- (-)-OSU6162在完全重返工作的患者中显著改善FSS评分的疲劳。
研究设计与样本
- 双盲、随机、安慰剂对照、单中心试验,纳入96例aSAH后疲劳患者,随机接受(-)-OSU6162(n=49)或安慰剂(n=47),剂量30-60 mg/日,治疗12周。
主要发现
- 治疗12周后,两组FSS、MFS和BDI评分均显著改善,BAI评分仅在安慰剂组改善。
- 两组SF-36活力维度均显著改善,神经心理测试基线正常且未受治疗影响。
- 完全重返工作的患者中,(-)-OSU6162组FSS评分明显改善。
- 合并使用抗抑郁药可增强(-)-OSU6162在第1周对FSS评分的疗效,超出安慰剂反应。
- 合并使用β受体阻滞剂或钙通道阻滞剂可增强(-)-OSU6162在第4周对MFS评分的疗效,超出安慰剂反应。
关键数值与推荐
- FSS、MFS、BDI评分在两组治疗12周后均显著改善。
- BAI评分仅在安慰剂组显著改善。
- SF-36活力维度在两组均显著改善。
- 神经心理测试表现基线在正常范围,未受治疗影响。
- (-)-OSU6162组头晕报告更频繁,但无严重不良事件归因于治疗。
临床怎么用
- (-)-OSU6162未显示优于安慰剂的整体疗效,不推荐常规用于aSAH后疲劳。
- 对于完全重返工作的aSAH后疲劳患者,(-)-OSU6162可能改善疲劳严重程度。
- 合并使用抗抑郁药、β受体阻滞剂或钙通道阻滞剂可能增强(-)-OSU6162的某些疗效,需进一步研究。
- 强烈的安慰剂反应提示可开发非药物治疗方案用于aSAH后疲劳。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Fatigue after aneurysmal subarachnoid hemorrhage (aSAH) is common and usually long-lasting, and it has a considerable negative impact on health-related quality of life (HRQOL), social functioning, and the ability to return to work (RTW). No effective treatment exists. The dopaminergic regulator (-)-OSU6162 has shown promising results regarding the mitigation of fatigue in various neurological diseases, and therefore the authors aimed to investigate the efficacy of (-)-OSU6162 in alleviating fatigue and other sequelae after aSAH. METHODS: A double-blind, randomized, placebo-controlled, single-center trial was performed in which 96 participants with post-aSAH fatigue were administered 30-60 mg/day of (-)-OSU6162 or placebo over a period of 12 weeks. Efficacy was assessed using the Fatigue Severity Scale (FSS), the Mental Fatigue Scale (MFS), the Beck Anxiety Inventory (BAI), the Beck Depression Inventory II (BDI-II), the SF-36 questionnaire, and a neuropsychological test battery. Assessments were performed at baseline, after 1, 4, 8, and 12 weeks of treatment, and at follow-up, 8 weeks after treatment. RESULTS: The 96 participants with post-aSAH fatigue were randomized to treatment with (-)-OSU6162 (n = 49) or placebo (n = 47). The FSS, MFS, and BDI scores improved significantly in both groups after 12 weeks of treatment, whereas the BAI scores improved in the placebo group only. HRQOL improved significantly in the SF-36 domain "Vitality" in both groups. Neuropsychological test performances were within the normal range at baseline and not affected by treatment. The FSS score was distinctly improved in patients with complete RTW upon treatment with (-)-OSU6162. Concomitant use of antidepressants improved the efficacy of (-)-OSU6162 on the FSS score at week 1 beyond the placebo response, and correspondingly the use of beta- or calcium-channel blockers improved the (-)-OSU6162 efficacy beyond the placebo response in MFS scores at week 4 of treatment. There was a significant correlation between improvement in FSS, BAI, and BDI scores and the plasma concentration of (-)-OSU6162 at the dose of 60 mg/day. No serious adverse events were attributable to the treatment, but dizziness was reported more often in the (-)-OSU6162 group. CONCLUSIONS: Fatigue and other sequelae after aSAH were similarly alleviated by treatment with (-)-OSU6162 and placebo. (-)-OSU6162 improved fatigue, as measured with the FSS score, significantly in patients with complete RTW. There seemed to be synergetic effects of (-)-OSU6162 and medications interfering with dopaminergic pathways that should be explored further. The strong placebo response may be exploited in developing nonpharmacological treatment programs for post-aSAH fatigue.
引用
- Western E, Nordenmark TH, Sorteberg W, et al. (-)-OSU6162 in the treatment of fatigue and other sequelae after aneurysmal subarachnoid hemorrhage: a double-blind, randomized, placebo-controlled study. J Neurosurg. 2021. PMID: 34715650. doi:10.3171/2021.7.JNS211305
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。